In addition to inducing Type 1 IFNs, co-stimulatory molecules (CD80, CD86, CD80) are also upregulated and targeting these pathways may assist in overcoming tumor-induced DC tolerance, particularly when designing therapies that manipulate the DC directly such as vaccines (166). Here, CD86 is linked to neoplasm.